MACK Latest News, Press Relases and Analysis

All

Press Releases

2 years ago - By: InvestorPlace

MACK Stock Earnings: Merrimack Pharmaceuticals Reported Results for Q1 2024

2 years ago - By: Merrimack Pharmaceuticals, Inc.

Merrimack Pharmaceuticals, Inc. Announces Stockholder Approval of Plan of Dissolution And Cash Liquidating Dividend Amount of $15.10 Per Share of Common Stock

2 years ago - By: Merrimack Pharmaceuticals, Inc.

Merrimack Pharmaceuticals, Inc. Announces Anticipated Final Cash Dividend Amount of Initial Liquidating Distribution, Subject to Receipt of Stockholder Approval of Plan of Dissolution

2 years ago - By: Merrimack Pharmaceuticals, Inc.

Merrimack Pharmaceuticals Announces Notification of Plan to Voluntary Delist Common Stock on NASDAQ Subject to Receipt of Stockholder Approval of Plan of Dissolution

2 years ago - By: InvestorPlace

MACK Stock Earnings: Merrimack Pharmaceuticals Reported Results for Q4 2023

2 years ago - By: Merrimack Pharmaceuticals, Inc.

Merrimack Receives $225 Million Milestone Payment from Ipsen

2 years ago - By: Merrimack Pharmaceuticals, Inc.

Merrimack Reports Full Year 2023 Financial Results

2 years ago - By: Merrimack Pharmaceuticals, Inc.

Merrimack Reports Ipsen Announcement of Approval By The US FDA of Onivyde® (Irinotecan Liposome Injection) Plus 5 Fluorouracil/Leucovorin and Oxaliplatin (NALIRIFOX) as a First-Line Treatment for Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC)

2 years ago - By: Benzinga - Mentions: TRMB F UNP

$2M Bet On Ford? Check Out These 4 Stocks Insiders Are Buying

2 years ago - By: Merrimack Pharmaceuticals, Inc.

Merrimack Reports Third Quarter 2023 Financial Results

2 years ago - By: Merrimack Pharmaceuticals, Inc.

Merrimack Reports Second Quarter 2023 Financial Results

3 years ago - By: Merrimack Pharmaceuticals, Inc.

Merrimack Reports First Quarter 2023 Financial Results

3 years ago - By: Benzinga - Mentions: JELD TFIN

3 Stocks Insiders Are Buying: Triumph Financial And More

3 years ago - By: InvestorPlace - Mentions: UPST BBBY DIS

Upstart (UPST) Stock Sinks on Gloomy Forecast

3 years ago - By: InvestorPlace - Mentions: JNCE STBX SWVL LYLT ...

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday

3 years ago - By: Merrimack Pharmaceuticals, Inc.

Merrimack Reports Full Year 2022 Financial Results

3 years ago - By: Merrimack Pharmaceuticals, Inc.

MERRIMACK PHARMACEUTICALS IN (MACK) Stock News

MACK Latest News, Press Relases and Analysis

MACK Stock Earnings: Merrimack Pharmaceuticals Reported Results for Q1 2024

Merrimack Pharmaceuticals, Inc. Announces Stockholder Approval of Plan of Dissolution And Cash Liquidating Dividend Amount of $15.10 Per Share of Common Stock

Merrimack Pharmaceuticals, Inc. Announces Anticipated Final Cash Dividend Amount of Initial Liquidating Distribution, Subject to Receipt of Stockholder Approval of Plan of Dissolution

Merrimack Pharmaceuticals Announces Notification of Plan to Voluntary Delist Common Stock on NASDAQ Subject to Receipt of Stockholder Approval of Plan of Dissolution

MACK Stock Earnings: Merrimack Pharmaceuticals Reported Results for Q4 2023

Merrimack Receives $225 Million Milestone Payment from Ipsen

Merrimack Reports Full Year 2023 Financial Results

Merrimack Reports Ipsen Announcement of Approval By The US FDA of Onivyde® (Irinotecan Liposome Injection) Plus 5 Fluorouracil/Leucovorin and Oxaliplatin (NALIRIFOX) as a First-Line Treatment for Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC)

$2M Bet On Ford? Check Out These 4 Stocks Insiders Are Buying

Merrimack Reports Third Quarter 2023 Financial Results

Merrimack Reports Second Quarter 2023 Financial Results

Merrimack Reports First Quarter 2023 Financial Results

3 Stocks Insiders Are Buying: Triumph Financial And More

Upstart (UPST) Stock Sinks on Gloomy Forecast

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday

Merrimack Reports Full Year 2022 Financial Results

Merrimack Pharmaceuticals Extends Section 382 Net Operating Loss Rights Plan